Opthea is developing a novel eye therapeutic for the treatment of eye diseases. We are a Melbourne based biotechnology company, with a very strong intellectual property platform.
Our novel treatment is called OPT-302, which is a new approach for the treatment of wet-age macular degeneration and diabetic macular edema.
The current therapies for these two eye diseases all block the same target and work very similarly. In terms of the clinical outcomes for patients, there is a large proportion of patients that do not respond adequately to ongoing treatments from current therapies on the market.
Our goal is to use OPT-302 in combination with these existing commercially successful treatments. The market opportunities for novel therapies such as OPT 302 is in excess of $10 billion per annum worldwide.